http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02083129-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_083c04acf0669fa1fa4ed591bf70ed21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10b19a637d662a6a26d60396e820eeae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90c0246036b501600aead4a0f2237992
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df53cdf55050f3f4580e1931741875b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ecfe1e7cc34f8691d958d7f18cecef39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7feeb09896157289d37b2e363c0b611
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1641
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-424
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-43
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-424
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-43
filingDate 2002-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_924a7ae0d9647a13e88cfa85ad1bafe7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8936d97b1a2ea05026eeb0729b6e1446
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f98cf491a44c1ff8b5c4e68afd89094f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_473be4ef8d7f1b799d5a01788b2d5576
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee39bf187e82fbe4b6a99e2a867246c6
publicationDate 2003-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-02083129-A3
titleOfInvention Pharmaceutical composition comprising clavulanic acid
abstract A pharmaceutical composition comprising an active ingredient and clavulanate wherein the clavulanate is in the form of granulated and hydrophobised particles; and intermediates in its preparation, e.g. clavulanate is granulated and/or hydrophobised form.
priorityDate 2001-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5827537-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9525516-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0041478-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9733564-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280980
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226420758
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535338
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226397639

Total number of triples: 37.